MAPT and Alzheimer disease: Advances in the development of in vivo biomarkers of beta-amyloid (Aβ), tau, and neurodegeneration have increased the ability to accurately detect Alzheimer’s disease (AD) neuropathologic changes, even before onset of clinical symptoms [1–9].